• Ayurcann Holdings (AYUR) has applied to trade on the OTCQB
  • Ayurcann is also working to secure DTC eligibility
  • The company will continue to trade on the CSE under its symbol AYUR
  • Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma-grade products
  • Ayurcann Holdings Corp. (AYUR) opened trading at C$0.26 per share

Ayurcann Holdings (AYUR) has filed an application to trade on the OTCQB.

The company will continue to trade on the CSE under its symbol AYUR.

Ayurcann is also working to secure DTC eligibility for electronic settlement and transfer of its common shares in the United States.

Trading on the OTCQB market enables companies to build investor awareness and provide U.S. investors with a facility to trade more easily.

Igal Sudman, CEO of Ayurcann, commented on the application.

“Ayurcann is excited to provide US institutional and retail investors this opportunity to join our journey through the OTCQB. We love our Canadian roots, but our plans and visions include being traded in the largest economy on the planet and demonstrate our investment capabilities in manufacturing quality cannabis derivates at an affordable price while maintaining healthy operating margins.”

The OTCQB listing remains subject to the approval of the OTCQB and the satisfaction of applicable listing requirements.

Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma-grade products for the adult-use and medical cannabis industry in Canada.

Ayurcann Holdings Corp. (AYUR) opened trading at C$0.26 per share.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.